- Company
- Janssen, Pharma distribution industry agree on margin adj
- by Son, Hyung Min Aug 1, 2025 06:18am
- The conflict between Janssen Korea and the pharmaceutical distribution industry over distribution margin reductions has been resolved with a negotiated settlement. The distribution industry achieved an outcome that maintains existing trade relationships, including with small and medium-sized distributors, while also improving the proposed mar
- Company
- NMOSD drug Enspryng’s reimbursement expanded in KOR
- by Whang, byung-woo Aug 1, 2025 06:16am
- Roche Korea announced on the 31st that the reimbursement criteria for Enspryng (satralizumab), a treatment for neuromyelitis optica spectrum disorder (NMOSD), will be expanded from August 1st per a notification from the Ministry of Health and Welfare. Enspryng is indicated for the treatment of adult patients with anti-aquaporin(AQP4) anti
- Company
- Roche's HR+ breast cancer drug 'Itovebi' wins nod in Korea
- by Whang, byung-woo Aug 1, 2025 06:15am
- Roche Korea announced on July 30 that it has received approval of the breast cancer treatment Itovebi (inavolisib) from the Ministry of Food and Drug Safety. Itovebi, recently approved, can be used for the treatment of PIK3CA mutation-positive, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breas
- Company
- Beyfortus likely to face restrictions on public advertising
- by Whang, byung-woo Jul 31, 2025 06:15am
- Sanofi is now compelled to revise its strategy as public advertising of Beyfortus (nirsevimab), an RSV preventive antibody injection, faces regulatory obstacles in Korea. According to Dailypharm’s coverage, the&160;Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA) Drug Advertising Review Committee ruled that Beyfortu
- Company
- MSD Korea begins Januvia drug price difference compensation
- by Son, Hyung Min Jul 31, 2025 06:14am
- There are changes regarding the Januvia drug price difference compensation issue, which had been stalled for nearly two years. MSD Korea has officially informed the distribution industry that it will begin accepting applications for Januvia compensation starting next month, August 1. However, this compensation is limited to the quantity sold
- Company
- GSK Korea appoints Gunnar Riediger as new General Manager
- by Whang, byung-woo Jul 31, 2025 06:14am
- GSK Korea announced on the 30th that it has appointed Gunnar Riediger as its new General Manager, effective August 1. The new GM joined GSK in 2004 through the company's global talent development program, the “Future Leaders Program,” and has led healthcare operations across Latin America for over 20 years. He has held key roles incl
- Company
- Lixiana solely leads DOAC mkt… Xarelto, Eliquis↓
- by Kim, Jin-Gu Jul 30, 2025 06:16am
- Original direct-acting oral anticoagulant (DOAC) drugs have faced mixed fortunes in the Korean market. Prescription sales of Lixiana (edoxaban) increased by 8% year-on-year, solidifying its lead in Korea’s market. Its market share in the DOAC market expanded to 49%, and the analysis is that Lixiana will continue its lead in the market
- Company
- Expanded reimb for Jardiance…management of CRM disease
- by Whang, byung-woo Jul 30, 2025 06:10am
- Boehringer Ingelheim announced on the 29th that its SGLT2 inhibitor, Jardiance (empagliflozin), will be reimbursed by the National Health Insurance for the treatment of chronic kidney disease (CKD), starting August 1, according to the Ministry of Health and Welfare notification. According to this notification, Jardiance will be reimbursed
- Company
- Neurophet partners with Roche for AI tech verification
- by Whang, byung-woo Jul 30, 2025 06:10am
- Neurophet (Co-CEO Jun-gil Bin, Dong-hyun Kim), a specialized AI company in brain disease diagnosis and treatment, announced on the 29th that it has officially signed a joint research agreement with Roche and has begun full-scale collaboration Neurophet has already been sharing data with Roche, and with the official announcement of the col
- Company
- Attention drawn to reimb status of 'Mounjaro' for diabetes
- by Moon, sung-ho Jul 30, 2025 06:09am
- As the official launch of Mounjaro (tirzepatide, Eli Lilly Korea), approved in Korea as an adjunct therapy for chronic weight management following its indication for adult type 2 diabetes, is imminent, the reimbursement status of the drug is garnering attention. The focus is on whether it will be recognized and reimbursed as the first 'innova
